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with persistent versus resolving inflammatory
arthritis
Dominika E Nanus1,2, Andrew D Filer1,3, Lorraine Yeo1, Dagmar Scheel-Toellner1, Rowan Hardy2, Gareth G Lavery2,
Paul M Stewart4, Christopher D Buckley1,5, Jeremy W Tomlinson6, Mark S Cooper7* and Karim Raza1,5Abstract
Introduction: Impairment in the ability of the inflamed synovium to generate cortisol has been proposed to be a
factor in the persistence and severity of inflammatory arthritis. In the inflamed synovium, cortisol is generated from
cortisone by the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme. The objective of this study was to
determine the role of endogenous glucocorticoid metabolism in the development of persistent inflammatory arthritis.
Methods: Urine samples were collected from patients with early arthritis (symptoms ≤12 weeks duration) whose final
diagnostic outcomes were established after clinical follow-up and from patients with established rheumatoid
arthritis (RA). All patients were free of disease-modifying anti-rheumatic drugs at the time of sample collection.
Systemic measures of glucocorticoid metabolism were assessed in the urine samples by gas chromatography/mass
spectrometry. Clinical data including CRP and ESR were also collected at baseline.
Results: Systemic measures of 11β-HSD1 activity were significantly higher in patients with early arthritis whose
disease went on to persist, and also in the subgroup of patients with persistent disease who developed RA,
when compared with patients whose synovitis resolved over time. We observed a significant positive correlation
between systemic 11β-HSD1 activity and ESR/CRP in patients with established RA but not in any of the early
arthritis patients group.
Conclusions: The present study demonstrates that patients with a new onset of synovitis whose disease
subsequently resolved had significantly lower levels of systemic 11β-HSD1 activity when compared with patients
whose synovitis developed into RA or other forms of persistent arthritis. Low absolute levels of 11β-HSD1 activity
do not therefore appear to be a major contributor to the development of RA and it is possible that a high total
body 11β-HSD1 activity during early arthritis may reduce the probability of disease resolution.Introduction
Glucocorticoids (GCs) regulate the body’s response to
stress and inflammation, glucose metabolism and many
other physiological processes. Secretion of endogenous
GCs from the adrenal cortex is controlled by the
hypothalamic-pituitary-adrenal (HPA) axis. In contrast
to exogenous GCs, which are widely prescribed for the
treatment of chronic inflammatory conditions, the role
of endogenous GCs in the development and resolution
of inflammation is less well characterised. Inadequate* Correspondence: mark.cooper@sydney.edu.au
7ANZAC Research Institute, Concord Repatriation General Hospital, University
of Sydney, Hospital Road, Sydney NSW 2139, Australia
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stated.endogenous GC synthesis during inflammation has been
proposed as an aetiological factor in the development of
rheumatoid arthritis (RA). The link between endogenous
GCs and the development of RA was initially thought due
to defects in the HPA axis [1]. This hypothesis has been
supported by clinical trials in which early GC treatment
has reduced the risk of patients with early inflammatory
arthritis developing persistent disease [2]. It is now known
that GC action at a tissue level can also be regulated by
local metabolism of GCs [3]. It has been previously dem-
onstrated that inflamed synovial tissue in patients with RA
can interconvert inactive and active GCs through the
expression of the 11β-hydroxysteroid dehydrogenase en-
zymes (11β-HSDs) [4,5]. The two primary isoenzymesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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that primarily converts hormonally inactive cortisone into
hormonally active cortisol, and 11β-HSD2 that solely inac-
tivates cortisol to cortisone [6].
The GC-activating capacity of synovial tissue explants
(a reaction carried out by 11β-HSD1) has been shown to
directly correlate with histological and clinical measures
of inflammation in patients with established RA [4,5].
These patients also have increased systemic measures of
11β-HSD1 activity that are significantly decreased upon
treatment with anti-tumour necrosis factor alpha (TNFα)
therapy [7]. This suggests that the observed upregulation
of 11β-HSD1 in established RA can, at least partially, be
explained by inflammation.
Despite there being a clear link between disease activ-
ity in established RA and activation of glucocorticoids by
11β-HSD1 within synovial tissue, it has been proposed
that there is a ‘relative’ deficiency in the amount of cortisol
synthesised in this condition compared to patients with
osteoarthritis [4,8]. This deficiency in cortisol production
could predispose to the persistence of inflammation.
These observations were, however, made in patients with
long-standing RA and the relationship between 11β-HSD1
activity and inflammation in patients with early untreated
inflammatory arthritis has not been explored.
Previous work thus raises the possibility that patients
with early arthritis are predisposed to develop persistent
arthritis if they have a deficiency in local 11β-HSD1-
mediated GC production. In this study, we examined
total body levels of 11β-HSD1 activity in a cohort of pa-
tients with early inflammatory arthritis and, in particular,
examined the relationship between enzyme activity and
the subsequent outcome of inflammatory arthritis.
Methods
Patients
Patients (all aged over 18) were part of the Birmingham
Early Arthritis Cohort (BEACON) and were recruited
from Sandwell and West Birmingham Hospitals NHS
Trust and University Hospitals Birmingham NHS Foun-
dation Trust.
All patients with early arthritis presented with clinic-
ally apparent synovial swelling and a symptom duration
of 12 weeks or less at the time of recruitment. The final
diagnostic outcome was determined after 18 months of
clinical follow-up when patients were assigned to one of
the following three outcome groups: (1) persistent inflam-
matory arthritis that did not fulfil the 1987 American Col-
lege of Rheumatology (ACR) classification criteria for RA
[9]; (2) persistent RA, according to the 1987 ACR classifi-
cation criteria [9]; (3) resolving inflammatory arthritis.
Patients were classified as having a resolving inflammatory
arthritis if they had no clinically apparent joint swelling at
final follow-up, were not receiving disease-modifyingdrugs or steroids and had not received such drugs in the
previous three months.
In addition, patients who fulfilled the 1987 ACR classi-
fication criteria for RA and had a symptom duration of
more than 12 weeks at initial assessment were recruited
as patients with ‘established RA’.
No patients in the current study received either gluco-
corticoid or disease-modifying anti-rheumatic drug ther-
apy prior to recruitment and the collection of baseline
urine or blood samples.
Clinical data including tender and swollen joint counts
were collected, C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) measured, and the 28-item dis-
ease activity score (DAS28) using ESR scores calculated
at the first appointment. Urine samples obtained from a
single void were collected in a standardised manner in
the mid-morning from all patients with early arthritis
and established RA at the first appointment, snap frozen,
and stored at -80°C. The study was conducted in compli-
ance with the Helsinki declaration and was approved by
the South Birmingham Local Research Ethics Committee.
All subjects gave written informed consent.Measurement of urinary corticosteroid metabolites
Urinary corticosteroid metabolite levels were measured
by gas chromatography/mass spectrometry (GC/MS) using
a 5970 mass spectrometer (Hewlett-Packard, Houston, TX,
USA) and a previously described method [10]. Systemic
(that is total body) measures of 11β-HSD1 activity were
calculated as the urinary (tetrahydrocortisol + 5αtetrahydro-
corticol)/tetrahydrocortisone ((THF + 5αTHF)/THE) ratio
and the cortols/cortolones ratio. The urinary-free cortisol/
cortisone ratio (UFF/UFE) was also measured, being a
sensitive indicator of changes in renal 11β-HSD2 activity.
As an additional control, the activity of another enzyme
system that metabolises cortisol, 5α-reductase, was
measured and was calculated as the urinary 5αTHF/
THF ratio. To determine whether these steroid ratios in
a mid-morning spot urine sample were representative of
complete 24-hour urine samples, we collected mid-
morning spot urine samples from six healthy volunteers
and compared results obtained from these with results
from total 24-hour urine collections obtained from the
same individuals. We found that the (THF + 5αTHF)/
THE) ratio measured in these spot urine samples were
highly correlated (r = 0.9590, P = 0.0025) with those
obtained on a 24-hour sample (Figure S1 in Additional
file 1). This confirmed that the measure of 11β-HSD1
activity obtained via a mid-morning urine sample accur-
ately reflected daily 11β-HSD1 activity. Therefore for
practical purposes, we used mid-morning spot urine
samples to measure indices of glucocorticoid metabol-
ism in the present study.
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All statistical tests were performed using GraphPad
Prism5, (GraphPad Software, San Diego, CA, USA). Nor-
mality of distribution of urine corticosteroid metabolite
ratios were examined by the Kolmogorov-Smirnov test.
When differences between different outcome groups were
compared, if the data were normally distributed the
unpaired t test was used. For non-normally distributed
variables the Mann-Whitney test was used. Given the ex-
ploratory nature of our analyses, the reported P values
were not adjusted for multiple comparisons. A P value
<0.05 was considered statistically significant. Correlation
analysis was performed using the Spearman’s test.Table 1 Demographic and clinical variables for patient with e
Outcome group Early resolving
arthritis
Early persistent
arthritis (All)
Ear
Number 24 31 18
Female 16 (67%) 21 (68%) 12 (
n (%)
Age, years; mean (SD) 51.8 (14.4) 56.9 (18.2) 60.7
CRP, mg/l; 8 (0-14) 25 (10-44) 27 (
Median (IQR)
ESR, mm/h; 20.5 (12-44.75) 26 (20-60.75) 24 (
Median (IQR)
DAS28, ESR; 3.7 (3.5-5.1) 5.3 (4.4-6.7) 6.1
Median (IQR)
Disease duration, weeks; 6.5 (4-9.5) 8 (6-10) 8 (5
Median (IQR)
Tender joint count 28; 2.5 (1-4.75) 7 (2-17) 8.5
Median (IQR)
Swollen joint count 28; 1 (1-3.5) 4 (1-11) 6.5
Median (IQR)
RF + ve 3 (12.5%) 10 (32%) 9 (5
n (%)
Anti-CCP antibodies 0 (0%) 9 (29%) 8 (4
n (%)
Early arthritis patients were assigned to one of the following three outcome groups
(column 3) and persistent RA (column 4; a subgroup of the persistent arthritis patie
RA (column 5). Data shown for normally distributed variables are mean (SD) values and
between different outcome groups for normally distributed clinical characteristics were
groups for non-normally distributed clinical characteristics were carried out using the M
persistent RA vs early resolving arthritis; early persistent RA vs established RA). Compa
were carried out using the chi-square test. A P value <0.05 was considered statistically
standard deviation; CRP, C-reactive protein; IQR, interquartile range; ESR, erythrocyte se
ESR; RF, rheumatoid factor; anti-CCP antibodies, anti-cyclic citrullinated peptide antiboResults
Systemic measures of GC metabolism in patients with
early arthritis in relation to clinical outcome and in
patients with established RA
In total, 75 patients were recruited to the study and had
full clinical assessment and urinary corticosteroid analysis.
Fifty-five patients had early arthritis (symptom duration
<12 weeks at initial recruitment) and 20 had established
RA (fulfilling 1987 ACR classification criteria and having a
symptom duration of >12 weeks at initial recruitment). Of
the 55 early arthritis patients 31 subsequently developed
persistent inflammatory arthritis (referred to as ‘early per-
sistent arthritis (all)’). Of these 31 patients, 18 fulfilledarly arthritis and established RA
ly persistent RA Established RA P
20 na
67%) 15 (75%) ns
2 (15.8) 58.2 (14.3) ns
10.75-68) 9 (0-44.75) P = 0.0221 Early p arthritis (all)
vs early resolving arthritis
P = 0.0184 Early p RA vs early
resolving arthritis
19.75-60.75) 25 (9.75-48.75) ns
(4.25-6.8) 5.3 (4.3-6.1) P = 0.0013 Early p arthritis (all)
vs early resolving arthritis
P = 0.0054 Early p RA vs early
resolving arthritis
.75-10) 42 (22.25-82.5) P < 0.0001 Established RA vs
early p RA
(2.75-15.5) 8.5 (4.25-19.75) P = 0.0072 Early p arthritis (all)
vs early resolving arthritis
P = 0.0072 Early p RA vs early
resolving arthritis
(3-13) 7 (4-13.5) P = 0.0034 Early p arthritis (all)
vs early resolving arthritis
P = 0.0001 Early p RA vs early
resolving arthritis
0%) 8 (40%) ns
4%) 11 (55%) P = 0.0004
after clinical follow-up: resolving arthritis (column 2), persistent arthritis
nts). In addition, data are shown for patients who presented with established
for non-normally distributed variables are median (IQR) values. Comparisons
carried out using the unpaired t test and comparison between different outcome
ann-Whitney test (early persistent arthritis (all) vs early resolving arthritis; early
risons between different outcome groups for gender and autoantibody status
significant. RA, rheumatoid arthritis; na, non applicable; ns, non significant; SD,
dimentation rate; DAS28, ESR, 28-item disease activity score calculated using
dies.
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ent RA’). Twenty-four of the 55 patients with early arth-
ritis had a resolving disease course (referred to as ‘early
resolving arthritis’). Demographic and clinical details of
participants are shown in Table 1.Ea
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Figure 2 Clinical measures of disease activity in patients with early arthritis and established RA. ESR (A) and CRP (B) levels in patients with early
resolving arthritis (circles), all patients with early persistent arthritis (squares), early persistent RA (upward triangles) and established RA (downward
triangles). Individual values and medians are represented on the graph. Data for ESR and CRP were not normally distributed; the Mann-Whitney
test was used for comparison between the outcome groups. A P value <0.05 was considered statistically significant. ESR, erythrocyte
sedimentation rate (mm/hour); CRP, C-reactive protein (mg/L). RA, rheumatoid arthritis.
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nificantly higher mean level of the THF + 5αTHF/THE
ratio when compared with patients in whom synovitis
subsequently resolved (Figure 1A). 11β-HSD1 activity in
patients with established RA was not significantly differ-
ent to that in the early persistent RA group. Examination
of cortols/cortolones ratios as an additional measure of
11β-HSD1 activity supported these findings, being signifi-
cantly greater in the early persistent arthritis and early
persistent RA groups compared to patients whose syno-
vitis subsequently resolved (Figure 1B). In addition,
there was no significant difference in this measure be-
tween early persistent RA patients and established RA
patients. There was no significant difference in the
UFF/UFE ratio (an indicator of renal 11β-HSD2 activity)
between early resolving arthritis patients and patients0 50 100 150
0
1
2
3 rho=0.3562
p=0.0018
All Patients
ESR (mm/hour)
(T
H
F+
5a
T
H
F)
/T
H
E
A
Figure 3 Correlation of ESR and CRP with global 11β-HSD1 activity in all p
ratio and ESR (A), and CRP (B). Correlation coefficient (rho) and the signific
correlation. ESR, erythrocyte sedimentation rate (mm/hour); CRP, C-reactive
(THF + 5αTHF)/THE ratio, (tetrahydrocortisol + 5αtetrahydrocorticol)/tetrahydwho subsequently developed RA or other forms of
persistent arthritis (Figure 1C). However, there was a
significant difference between early persistent RA and
established RA.
There was no significant difference between the outcome
groups in 5αTHF/THF ratio, a measure of 5α-reductase
activity (Figure 1D).
Clinical measures of disease activity in patients with early
arthritis and established RA
Inflammation is known to influence 11β-HSD1 activity
in vivo [7]. To understand the possible influence of levels
of inflammation on the observed differences in global
11β-HSD1 activity between different groups of early
arthritis patients, we compared the levels of ESR and
CRP in these groups (Figure 2A-B). Levels of ESR were0 100 200 300
0
1
2
3 rho=0.4037
p=0.0004
All Patients
CRP (mg/l)
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5a
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atients analysed together. Correlation between (THF + 5αTHF)/THE
ance of the correlation (P value) were calculated using Spearman’s
protein (mg/L). 11β-HSD, 11β-hydroxysteroid dehydrogenase type 1;
rocortisone ratio.
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Figure 4 (See legend on next page.)
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Figure 4 Correlation of ESR and CRP with global 11β-HSD1 activity in patients with early arthritis and established RA analysed individually.
Correlation between (THF + 5αTHF)/THE ratios and: ESR in established RA patients (A), CRP in established RA patients (B), ESR in all patients with
early persistent arthritis (C), CRP in all patients with early persistent arthritis (D), ESR in early persistent RA patients (E), CRP in early persistent
RA patients (F), ESR in early resolving arthritis patients (G) and CRP in early resolving arthritis patients (H). Correlation coefficient (rho) and the
significance of the correlation (P value) were calculated using Spearman’s correlation. ESR, erythrocyte sedimentation rate (mm/hour); CRP,
C-reactive protein (mg/L). 11β-HSD, 11β-hydroxysteroid dehydrogenase type 1; CRP, C-reactive protein (mg/L); RA, rheumatoid arthritis.
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groups (Figure 2A). However, the baseline level of CRP in
patients with early synovitis that persisted was higher than
that in patients whose synovitis resolved (Figure 2B).
Relationship between inflammation and 11β-HSD1
activity in patients with early arthritis and established RA
We assessed the relationship between 11β-HSD1 activ-
ity and ESR/CRP in the different disease groups. The
level of global 11β-HSD1 activity, measured as the
(THF + 5αTHF)/ THE ratio, correlated significantly with
ESR and CRP when all patients were analysed together
(Figure 3A-B). Similarly, a significant positive correlation
was observed in patients with established RA, where pa-
tients with the greatest increase in the ESR (Figure 4A)
and in CRP (Figure 4B) had also greatest increase in the
(THF + 5αTHF)/THE ratio. In contrast, there were no sta-
tistically significant correlations between ESR or CRP and
systemic 11β-HSD1 activity in any of the early arthritis
patients group (Figure 4C-H). Correlations between cor-
tols/cortolones ratio and ESR/CRP in different outcome
groups followed a pattern similar to the (THF + 5αTHF)/
THE data and are presented in Figure 5.
Discussion
This study shows that patients with a new onset of syno-
vitis whose disease subsequently resolved had significantly
lower levels of systemic 11β-HSD1 activity at presentation
when compared with patients whose synovitis persisted.
This observation appears contrary to that predicted on the
basis of previous work examining 11β-HSD1 activity in
patients with established rheumatic diseases. Specifically,
these data do not support the hypothesis that the develop-
ment of persistent arthritis is associated with a defect in
local GC production via reduced 11β-HSD1 activity at the
earliest stages of clinically apparent disease. By contrast,
these data raise the possibility that a high total body 11β-
HSD1 activity during early arthritis may reduce the prob-
ability of disease resolution.
Our previous work has demonstrated that both systemic
measures of 11β-HSD1 activity and also local GC activa-
tion within the synovium of patients with established RA
are related to the extent of inflammation as measured by
the ESR [5]. In the current study, we did not observe a sig-
nificant difference in the ESR levels measured between pa-
tients with early arthritis of different outcomes. However,we did observe a significant difference in the level of CRP.
Patients with early persistent arthritis had significantly
higher levels of CRP than patients with resolving synovitis,
mirroring the increase observed in systemic 11β-HSD1
activity in the early persistent group. It is possible that
the difference in global 11β-HSD1 activity observed be-
tween patients with early persistent arthritis and pa-
tients with early resolving arthritis may be explained, in
part, by a difference in the degree of inflammation. Cer-
tainly, in vitro experiments on mesenchymal cell popula-
tion demonstrate that 11β-HSD1 is positively regulated by
pro-inflammatory cytokines that are elevated in RA [11].
To better understand this phenomenon in vivo, we have
investigated the relationship between inflammation and
global 11β-HSD1 activity. When all patients were analysed
together, we found a positive correlation between mea-
sures of inflammation and the GCs activating capacity of
the 11β-HSD1 system (as previously described). Statisti-
cally, this relationship was even stronger in the group of
patients with established RA. In contrast, we were not able
to detect a statistically significant relationship between
these parameters at an early stage of arthritis. The
pathological processes governing the earliest clinically
apparent phases of RA are not fully understood. It has
been suggested that mechanisms operating at the onset
of RA are distinct from those observed at the later phase
of disease [12]. It is possible that differences in synovial
pathology in the early and established phases of RA lead
to different relationships between synovial inflammation
and global 11β-HSD1 activity in the early and estab-
lished phases of RA.
Based on the current findings, it is possible that high
local production of active GCs may not be necessary for
the resolution phase of early arthritis, and in fact that
high total body 11β-HSD1 activity observed during early
arthritis might be mechanistically linked to persistence.
Glucocorticoids are powerful immunomodulators [13].
High doses of exogenous GCs are well known for their
anti-inflammatory and immunosuppressive properties.
However, it has recently been proposed that, in certain sit-
uations, endogenous GCs have a pro-inflammatory rather
than anti-inflammatory effect [14]. For example, corticoste-
roids produced during exposure to an acute restraint stress
can potentiate the pro-inflammatory response of microglia
to lipopolysaccharide (LPS), whilst in the chronic collagen-
induced arthritis (CIA) mouse model, 11β-HSD1 inhibition
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Figure 5 (See legend on next page.)
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Figure 5 Correlation of ESR and CRP with global 11β-HSD1 activity in patients with early arthritis and established RA analysed individually. Correlation
between cortols/cortolones ratio and: ESR in all recruited patients analysed together (A), CRP in all recruited patients analysed together (B), ESR in
established RA patients (C), CRP in established RA patients (D), ESR in all patients with early persistent arthritis (E), CRP in all patients with early
persistent arthritis (F), ESR in early persistent RA patients (G), CRP in early persistent RA patients (H), ESR in early resolving arthritis patients (I),
CRP in early resolving arthritis patients (J). Correlation coefficient (rho) and the significance of the correlation (P value) were calculated using
Spearman’s correlation. ESR, erythrocyte sedimentation rate (mm/hour); CRP, C-reactive protein (mg/L). 11β-HSD, 11β-hydroxysteroid
dehydrogenase type 1; RA, rheumatoid arthritis.
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flammation [15,16]. This offers an explanation as to why
synovitis persists in patients with a higher level of 11β-
HSD1 activity, where high concentrations of endogenous
GCs instead of contributing to resolution might paradox-
ically be driving the persistence of RA by augmenting in-
flammation. However, these observations are in contrast
to findings in the acute K/BxN inflammatory arthritis
model where global transgenic knock-down of 11β-HSD1
exacerbated both the intensity and duration of acute in-
flammation [17]. 11β-HSD1 thus appears to deliver con-
trasting actions in the context of different inflammatory
arthritis models, with different observation in acute re-
solving and chronic persistent models.
An alternative explanation for our data is that local
11β-HSD1 activity is important for disease resolution in
patients with early arthritis but that the extent of the
elevation observed in patients with persistent disease is
inadequate given the level of inflammation observed in
these individuals. To fully dissect the role of endogenous
GC metabolism in driving persistence versus resolution
in patients with early arthritis, a clinical study would be
required using an 11β-HSD1 inhibitor in patients with a
new onset of inflammatory joint disease. The contrasting
evidence based on different murine models of arthritis
suggests that endogenous GCs might play different roles
during the onset and persistence phases of RA.
The observed high levels of global 11β-HSD1 activity
in the group of patients that went on to develop persist-
ent arthritis, including RA, might contribute to some of
the early extra-articular features of RA including early
osteoporosis [18], muscle loss [19], and cardiovascular
changes [20]. It was recently shown in animal models that
11β-HSD1 inhibition can be beneficial in attenuating ath-
erosclerosis [21]. Therefore, targeting the 11β-HSD1 sys-
tem could impact some of the extra-articular as well as
articular manifestations of RA.
We have previously reported that synovial tissue 11β-
HSD1 activity increases in response to inflammation and
this tissue is the most likely source of the additional
11β-HSD1 activity seen in patients with inflammatory
arthritis. However, this is not necessarily the only tissue
that could influence global measures of 11β-HSD1 in pa-
tients with early arthritis. Using the techniques employedhere, it was impossible to determine the tissue that con-
tributed most to the global measures of 11β-HSD1 activity
used in this study. At a tissue level the amount of GC ex-
posure will depend on both local production and the con-
tribution from the circulation (which is regulated by the
HPA axis). The measures of 11β-HSD1 described here
were based on mid-morning urine samples. The benefit of
these measures is that they depend on ratios of metabo-
lites as opposed to absolute levels of metabolites, which
are known to change during the day. To confirm the val-
idity of our approach we showed that mid-morning ratios
closely reflected the 24-hour picture. It should also be
emphasised that these measures of glucocorticoid metab-
olism are independent of changes in the HPA axis. How-
ever, for a complete evaluation of total tissue GC exposure
(including components from circulating GCs and from lo-
cally generated GCs) additional studies would require
multiple sampling of serum levels in association with 24-
hour measurements of total cortisol metabolite excretion.
This would allow an analysis of the systemic GC response
in addition to the local tissue response described here and
could give insight into whether there was a relationship
between the local tissue response and the systemic, circu-
latory, response in these conditions.
Conclusions
This study has, for the first time, examined the levels of
global 11β-HSD1 activity in patients with early arthritis
that subsequently either persisted or resolved. We found
that patients with resolving synovitis had significantly
lower levels of global 11β-HSD1 activity when compared
with patients whose arthritis developed into RA or other
form of persistent arthritis. The extent to which this in-
creased level of global 11β-HSD1 activity observed in pa-
tients with persistent arthritis contributes to and/or drives
persistence remains to be clarified.
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